Document is current

Article History

First Online: 25 April 2023

Einhaltung ethischer Richtlinien

:

: C. Denkert: AstraZeneca (Consulting Fees [e.g., advisory boards]); Daiichi Sankyo (Consulting Fees [e.g., advisory boards]); Lilly (Consulting Fees (e.g., advisory boards)); Molecular Health (Consulting Fees [e.g., advisory boards]); MSD Oncology (Consulting Fees (e.g., advisory boards)); Roche (Consulting Fees [e.g., advisory boards]); Sividon Diagnostics (Ownership Interest [stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds]); VMScope (Receipt of Intellectual Property Rights/Patent Holder, Royalty). F.R. Rodepeter: AstraZeneca (Lecture Fees). R. Erber: Honoraria: Roche, Eisai, Pfizer, BioNTech, Veracyte (PROCURE), Diaceutics, Mindpeak, AstraZeneca, Novartis. Forschungsunterstützung: AstraZeneca, Roche, NanoString Technologies, Biocartis, ZytoVision, Novartis, Cepheid, Mindpeak, MSD, Gilead, palleos healthcare, BioNTech. A. Lebeau: AstraZeneca (Consulting and Lecture Fees); Daiichi Sankyo (Consulting and Lecture Fees); MSD Sharp@Dhome (Consulting and Lecture Fees); Roche Pharma AG (Consulting and Lecture Fees; Study Support); Myriad Genetics (Lecture Fees); Novartis (Consulting and Lecture Fees); Diaceutics (Consulting Fees); QuIP GmbH (Consulting Fees). E. Mack: Roche, Boehringer Ingelheim (Lecture Fees). P. Jank: Myriad Genetics Inc. (stock ownership). J. Teply-Szymanski, M. Romey, A. Grass, T.S. Tarawneh, N. Gremke, J. Boekhoff, T. Wündisch und U. Wagner geben an, dass kein Interessenkonflikt besteht.

: Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.